Literature DB >> 11655130

Ethical decision making about animal experiments.

F Barbara Orlans.   

Abstract

Laboratory animals, being vulnerable subjects, need the protection provided by adequate ethical review. This review falls primarily to Institutional Animal Care and Use Committees. A review committee's first duty is to identify which procedures ethically are unacceptable irrespective of any knowledge that might be derived. Examples are provided. These projects should be disapproved. Then, "on balance" judgments are assessed that weigh the animal harms against the potential benefits to humans. Several countries (but not the United States) use a classification system for ranking the degree of animal pain and distress. This type of assessment is essential for careful ethical analysis. Another way to enhance ethical discussion is to strive for a more balanced perspective of different viewpoints among members of decision making committees. Inclusion of representatives of animal welfare organizations and a greater proportion of nonanimal researchers would likely achieve this objective.

Entities:  

Keywords:  Biomedical and Behavioral Research; Guide for the Care and Use of Laboratory Animals (National Research Council)

Mesh:

Year:  1997        PMID: 11655130     DOI: 10.1207/s15327019eb0702_7

Source DB:  PubMed          Journal:  Ethics Behav        ISSN: 1050-8422


  26 in total

1.  Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses.

Authors:  Ralf Geiben-Lynn; John R Greenland; Kwesi Frimpong-Boateng; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2008-02-13

2.  SERPINA3 Silencing Inhibits the Migration, Invasion, and Liver Metastasis of Colon Cancer Cells.

Authors:  Long-Lei Cao; Xu-Feng Pei; Xu Qiao; Jie Yu; Hui Ye; Chang-Lei Xi; Pei-Yun Wang; Zhi-Lin Gong
Journal:  Dig Dis Sci       Date:  2018-05-31       Impact factor: 3.199

3.  CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses.

Authors:  Ralf Geiben-Lynn; John R Greenland; Kwesi Frimpong-Boateng; Nico van Rooijen; Avi-Hai Hovav; Norman L Letvin
Journal:  Blood       Date:  2008-09-10       Impact factor: 22.113

4.  Non-classical natural killer T cells modulate plasmid DNA vaccine antigen expression and vaccine-elicited immune responses by MCP-1 secretion after interaction with a beta2-microglobulin-independent CD1d.

Authors:  Ralf Geiben-Lynn; John R Greenland; Kwesi Frimpong-Boateng; Norman L Letvin
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

5.  Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus.

Authors:  Qing-Jiu Zhang; Jie Li; Song-Yun Zhang
Journal:  Mol Neurobiol       Date:  2017-02-09       Impact factor: 5.590

6.  Factors Influencing IACUC Decision Making: Who Leads the Discussions?

Authors:  Jerald Silverman; Charles W Lidz; Jonathan Clayfield; Alexandra Murray; Lorna J Simon; Louise Maranda
Journal:  J Empir Res Hum Res Ethics       Date:  2017-06-29       Impact factor: 1.742

7.  Suppression of TLR4/NF-κB Signaling Pathway Improves Cerebral Ischemia-Reperfusion Injury in Rats.

Authors:  Hang Zhao; Zhuo Chen; Li-Juan Xie; Gui-Feng Liu
Journal:  Mol Neurobiol       Date:  2017-06-17       Impact factor: 5.590

8.  MiR-181b inhibits P38/JNK signaling pathway to attenuate autophagy and apoptosis in juvenile rats with kainic acid-induced epilepsy via targeting TLR4.

Authors:  Li Wang; Li-Fang Song; Xiao-Yi Chen; Yan-Li Ma; Jun-Fang Suo; Jing-He Shi; Guo-Hong Chen
Journal:  CNS Neurosci Ther       Date:  2018-05-28       Impact factor: 5.243

9.  Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta.

Authors:  Kwesi Frimpong-Boateng; Nico van Rooijen; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

10.  Anti-HSV activity of serpin antithrombin III.

Authors:  Debra C Quenelle; Tracy L Hartman; Robert W Buckheit; Mark N Prichard; Ralf Geiben Lynn
Journal:  Int Trends Immun       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.